Skip to content
Screener

Danaher DHR Recurring revenue — Sales

Other product segments

Nonrecurring revenue
$1.07B+10.2%

Similar metrics at other companies

Veralto logo
VLTORecurring — Sales
$915M+8.8%
Ralliant Corp logo
RALTest and Measurement — Sales
$210.2M+11.5%
DXP Enterprises logo
DXPEOrganic Sales — Sales
$526.61M+11.1%
DXP Enterprises logo
DXPEAcquisition Sales — Sales
$49.85M+103%
Aebi Schmidt Holding AG logo
AEBIAfter Sales — Sales
$73.88M+59.6%
Vontier logo
VNTSales of products — Sales
$691.9M+0.9%

Other financials

Income statement

See full
Revenue$6.3B+5.5%
Gross profit$3.6B+2.5%
Operating income$1.1B+48.3%
Net income$870.0M+56.8%
EPS (diluted)$1.23+59.7%

Balance sheet

See full
Cash & equivalents$4.3B+47.0%
Total debt$27.9B+50.1%
Total equity$52.6B+0.5%
Total assets$92.4B+13.2%

Cash flow

See full
Operating cash flow$1.5B+14.6%
CapEx$269.0M+8.5%
Free cash flow$1.3B+16.1%

Valuation

See full
Market cap$136.93B+0.4%
Enterprise value$160.44B+5.5%
P/E34.2×-5.7×
P/S5.5×-0.2×

Profitability

See full
Gross margin58.5%-1.1pp
Operating margin20.4%+2.0pp
Net margin15.9%+1.7pp
FCF margin21.8%+1.5pp

Returns & leverage

See full
Return on equity7.6%+1.0pp
Debt / equity0.5×+0.2×
Current ratio1.7×0.0×

Where this comes from

Reported directly by Danaher in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Danaher’s 10-Q, filed July 21, 2026.

Filed
Jul 20, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000313616-26-000161
For the Three-Month Period Ended June 26, 2026:Biotechnology / For the Three-Month Period Ended June 26, 2026:Life SciencesDiagnosticsTotal
High-growth markets(c)5745738111,958
Total$1,920$1,879$2,466$6,265
Revenue type:
Recurring$1,722$1,268$2,210$5,200
Nonrecurring1986112561,065
Total$1,920$1,879$2,466$6,265
For the Three-Month Period Ended June 27, 2025:
Geographical region:

Item 1. Financial Statements

FAQ

What is Danaher's recurring revenue — sales?
Danaher (DHR) reported recurring revenue — sales of $5.2B in Q2 2026.
How has Danaher's recurring revenue — sales changed year-over-year?
Danaher's recurring revenue — sales increased by 4.6% year-over-year, from $4.97B to $5.2B.
What is the long-term trend for Danaher's recurring revenue — sales?
Over 4 years (2021 to 2025), Danaher's recurring revenue — sales has grown at a 1.3% compound annual growth rate (CAGR), from $19.14B to $20.13B.
What does recurring revenue — sales mean?
This metric represents the portion of total revenue derived from ongoing, predictable streams such as service contracts, consumables, and software subscriptions. It serves as a key indicator of the stability and long-term visibility of the company's business model within its life sciences and diagnostics segments. By isolating these repeatable revenue sources, investors can better assess the company's resilience against cyclical market fluctuations.

Ask your AI about Danaher's recurring revenue — sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude